Disease · EFO_0003913
Comparisons in its trials14
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 14 of 14
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ranolazine vs Placebo: deaths from any cause | 14 of 142 | 11 of 142 | 284 | NCT01342029 | Trial comparisons |
| Ranolazine vs Placebo: serious adverse events | 6 of 142 | 1 of 142 | 284 | NCT01342029 | Trial comparisons |
| Erenumab 140 mg vs Placebo: deaths from any cause | 0 of 44 | 0 of 44 | 88 | NCT02575833 | Trial comparisons |
| Erenumab 140 mg vs Placebo: serious adverse events | 0 of 44 | 1 of 44 | 88 | NCT02575833 | Trial comparisons |
| Ranolazine Plus Exercise vs Placebo Plus Exercise: deaths from any cause | 0 of 18 | 0 of 19 | 37 | NCT01948310 | Trial comparisons |
| Ranolazine Plus Exercise vs Placebo Plus Exercise: serious adverse events | 0 of 18 | 0 of 19 | 37 | NCT01948310 | Trial comparisons |
| Ranolazine Treated vs Placebo: deaths from any cause | 0 of 16 | 0 of 17 | 33 | NCT02252406 | Trial comparisons |
| Ranolazine Treated vs Placebo: serious adverse events | 0 of 16 | 0 of 17 | 33 | NCT02252406 | Trial comparisons |
| Ranolazine vs Placebo: deaths from any cause | 0 of 11 | 0 of 11 | 22 | NCT02147067 | Trial comparisons |
| Ranolazine vs Placebo: serious adverse events | 0 of 11 | 0 of 11 | 22 | NCT02147067 | Trial comparisons |
| SAR407899 vs Placebo: deaths from any cause | 0 of 5 | 0 of 5 | 10 | NCT03236311 | Trial comparisons |
| SAR407899 vs Placebo: serious adverse events | 0 of 5 | 0 of 5 | 10 | NCT03236311 | Trial comparisons |
| 0.1% Capsaicin Cream First, Then Placebo vs Placebo First, Then 0.1% Capsaicin: serious adverse events | 0 of 3 | 0 of 4 | 7 | NCT01231750 | Trial comparisons |
| Ranolazine vs Sugar Pill: serious adverse events | 0 of 3 | 0 of 2 | 5 | NCT02147834 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0003913/comparisons